360 results about "Radical radiotherapy" patented technology

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The invention relates to the technical field of radiation therapy, in particular to a boron neutron capture therapy beam shaping device and a boron neutron capture therapy system. The beam shaping device for boron neutron capture therapy is used for beam shaping of a DT neutron tube generator. The interior of the beam shaping device is provided with a particle beam channel, and the particle beam channel is used for generating an initial neutron source through an incident proton beam. The beam shaping device comprises a value-added layer, a moderator, a filter layer, a reflecting layer, a collimator and a shielding layer, wherein the value-added layer, the moderator, the filter layer and the collimator are sequentially arranged from a target material to an outlet. And the axes of the particle beam channel, the value-added layer, the moderator and the collimator coincide. According to the beam shaping device, 14Mev high-energy neutrons from the DT neutron tube generator are shaped into hot / slow neutron beams meeting the BNCT treatment requirements, and impurities of fast neutrons and gamma rays are reduced to the maximum extent, so that the dosage precision and biological selectivity of treatment are effectively improved.

Systems and methods for guiding radiation therapy including providing particle radiation to a region of interest of a subject and receiving volumetric ionizing radiation acoustic imaging (iRAI) data and ultrasound imaging data from the region of in response the particle radiation. Further, from the iRAI data and the ultrasound imaging, a position of the particle radiation in the region of interest is determined, that position being a treatment position of the particle radiation. Further, the systems and methods determine one or more parameters of the particle radiation for adjusting in response to the determination of the position.

The present application provides methods of treating cancer in a subject involving administering to the subject an SHP-1 inhibitor (e.g., TPI-1 or an analog or derivative thereof) and a pro-inflammatory agent (e.g., a TLR agonist, radiation therapy, or an immune checkpoint inhibitor). In some cases, the methods involve administering an SHP-1 inhibitor when the individual is in an inflammatory response.

The invention provides radiation sensitive compositions and substrates coated with radiation sensitive compositions wherein the composition comprises a combination of metals and / or metalloid compounds, a functionalized or unfunctionalized acetylenic compound, and other optional ingredients such as amelioration agents. The invention further provides radiation sensitive devices for detection or measurement of radiation comprising substrates coated with these radiation sensitive compositions. The radiation sensitive compositions and devices have applications in dentistry, non-destructive testing, oncology, radiology, and radiotherapy, among others.

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The present disclosure relates to the field of radiation therapy and methods, software and systems for treatment planning.

Example methods and systems for kinematic calibration of a treatment couch for radiation therapy are described. In one example, a computer system may generate and send first instruction(s) to cause the treatment couch to move towards each of multiple calibration poses. The treatment couch may be associated with a kinematic model. The computer system may determine multiple measured poses that are associated with the respective multiple calibration poses. Next, the computer system may determine geometric correction data for updating the kinematic model based on the multiple measured poses. The computer system may then generate and send second instruction(s) to update the kinematic model associated with the treatment couch based on the geometric correction data.

A method may include obtaining input data relating to a target treatment plan for performing radiotherapy on a lesion using a radiation device. The input data may include a first target image of the lesion. The method may also include obtaining a segment shape estimation model. The method may also include estimating, based on the segment shape estimation model and the input data, a plurality of target location combinations of the target treatment plan and a plurality of target segment shapes of a collimator of the radiation device. One of the plurality of target location combinations may indicate a location of the collimator relative to the lesion. Each of the plurality of target segment shapes may correspond to one of the plurality of target location combinations.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. The methods may enhance the cancer treatment, improve the prognosis of the cancer patient, improve the survival of the cancer patient, and provide beneficial clinical effects and advantages to the patient.

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

A method for treating liver cancer, in particular in subjects exhibiting homologous recombination deficiency (HRD) positive, comprises the use of hydroxyurea methyl acyl fulvene. The compounds may be administered as monotherapy or in combination with other chemotherapeutic agents and / or radiation therapy.

A system and method for generation and use of radiation outcome prediction (response & side effects) score for patients undergoing radiotherapy for various medical conditions wherein the score is a personalized score, provided by analyzing multiple parameters including the tumor specific, patient specific, gene specific and treatment planning specific parameter(s), during and post therapy.

A radiotherapy system comprising a radiation delivery system 100 and a computer data store configured to store a radiotherapy treatment plan. The radiotherapy treatment plan comprises a plurality of c

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

An automated radiotherapy planning system for generating a deliverable radiotherapy plan (31) for a patient, to be delivered by a predefined radiotherapy delivery system, the system is configured to segment a target volume and one or more organs at risks in a 3D medical image of the patient, generate a prediction of a 3D volumetric dose distribution, generate the deliverable radiotherapy plan (31) and send the deliverable radiotherapy plan (31) to a predefined radiotherapy delivery system for final verification and execution.

The present embodiments relate generally to enabling an end user - e.g. medical physicists - to monitor radiation therapy and, with integration to the LINAC, adaptive radiotherapy. Embodiments record signals already released during radiotherapy, requiring no new irradiation of the patient for in vivo, in line, dose monitoring. Furthermore, as the transducers will be coupled to the patient with ultrasound gel, the present embodiments are not invasive to patients and will not introduce new discomfort during therapeutic procedures. The addition of the RiAD system provides the end user with additional information during the treatment of the patient, allowing for real-time beam tracking and dosimetry, enabling the end user to practice adaptive radiotherapy. The RiAD system enables the end user to ensure that proper dose delivery is occurring with each new beamlet and dose deposition, empowering them to adapt the medical treatment as it is performed and increase its precision in conventional electron beam radiotherapy, electron FLASH radiotherapy, and intraoperative electron beam radiotherapy.

The present disclosure provides a method of treating a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a T cell checkpoint inhibitor in combination with chemotherapy and / or radiation therapy; wherein the subject has a reduced level of CD73 protein or CD73 activity compared to a normal subject. In some aspects, the methods comprise further administration of a CD73 inhibitor prior to or contemporaneously with a combination of a T cell checkpoint inhibitor and chemotherapy and / or radiation therapy.

A method of treating a tumor in a subject, the method comprises applying a tumor treating field to the tumor at a frequency between approximately 50 kHz and approximately 1,000 kHz; and delivering personalized ultra-fractionated adaptive radiotherapy (PULSAR) regimen.

The present disclosure relates to systems and methods for generating and evaluating radiotherapy treatment plans. In an example, a system may include at least one processor configured to obtain data associated with a three-dimensional (3D) scan of a portion of a patient and at least one optimization objective; generating a set of radiotherapy treatment plans based on the 3D scan; and evaluating each radiation therapy treatment plan in the set of radiation therapy treatment plans based on the kernel function. The kernel function may include a metric evaluation function and a modification function based on the at least one optimization objective. In an example, the at least one processor may be configured to determine a selected radiation therapy treatment plan from a set of radiation therapy treatment plans based on comparing a cost of the selected radiation therapy treatment plan to a cost of each of the radiation therapy treatment plans.

Methods and devices are provided for fabricating and employing patient immobilization devices during radiation treatment procedures. Immobilization devices are provided that include a thin conformal shell configured to conform to an anatomical region of a patient that is to be exposed to radiation during a radiation treatment procedure, with a rigid lattice structure extending outwardly, in an external, beam-facing direction, from the conformal shell. The rigid lattice structure confers structural rigidity to the device, and the thin cellular regions mitigate the impact of the device on a surface dose delivered to the patient or subject. The present mechanical-metamaterial-based immobilization devices incorporate structural features that confer advantageous mechanical properties and radiation transmissive properties when compared with conventional solid or mesh-based immobilization devices used in radiation therapy.

The present application provides a method of treating cancer in an individual, the method comprising administering to the individual a tyrosine kinase inhibitor and an inflammatory agent (such as a TLR agonist, a STING activator, radiation therapy, or an immune checkpoint inhibitor). In some cases, the method involves administering the tyrosine kinase inhibitor when the individual is under inflammatory conditions. In one aspect, the present application provides a method of treating cancer in an individual, the method comprising administering to the individual a) a tyrosine kinase inhibitor and b) an inflammatory agent, optionally comprising intermittently administering the tyrosine kinase inhibitor to the individual.

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

Systems, methods, and computer software are disclosed that allow the automatic recalling of imaging parameters from computer memory for controlling an MRI system to perform treatment-day scans of a patient on a treatment couch in a radiotherapy system, prior to treatment. The treatment-day scans can be automatically initialized and the MRI system can then be controlled to perform the treatment-day scans according to the recalled imaging parameters. Reoptimized radiation treatment plan(s) can be automatically generated and predicted doses to anatomical structures of the patient based on the plan(s) can be displayed. Clinicians can be enabled to perform numerous reoptimization tasks simultaneously through parallel workflow interfaces and then a radiation therapy device can be controlled to deliver radiation according to a selected radiation treatment plan.